Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 10:17 p.m.

    📋 ADAPTIMMUNE THERAPEUTICS PLC (ADAP) - Regulatory Update

    Filing Date: 2022-05-25

    Accepted: 2022-05-25 06:42:19

    Event Type: Regulatory Update

    Event Details:

    Adaptimmune Therapeutics plc (ADAP) Announces Regulatory Update Adaptimmune Therapeutics plc (ADAP) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (ADAPTIMMUNE THERAPEUTICS PLC):

    Product Type Development Stage Therapeutic Area Source
    ADP-A2M4 in combination with pembrolizumab. GENETIC Phase PHASE2 Head and Neck Cancer ClinicalTrials.gov
    Autologous genetically modified ADP-A2M4CD8 cells GENETIC Phase PHASE2 Esophageal Cancer ClinicalTrials.gov
    Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation RADIATION Phase PHASE1 Urinary Bladder Cancer ClinicalTrials.gov
    Autologous genetically modified MAGE-A4ᶜ¹º³²T cells GENETIC Phase PHASE1 Urinary Bladder Cancer ClinicalTrials.gov
    ADP adoptive cell therapy BIOLOGICAL Phase PHASE1 Neoplasms ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    GSK4427296 DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    GSK3845097 DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    GSK3901961 DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    Experimental: Letetresgene autoleucel DRUG Phase PHASE2 Neoplasms ClinicalTrials.gov
    Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks GENETIC Phase PHASE1 Endometrial Cancer ClinicalTrials.gov
    Proleukin DRUG Phase PHASE1 Melanoma Stage III ClinicalTrials.gov
    Fludarabine Phosphate DRUG Phase PHASE1 Melanoma Stage III ClinicalTrials.gov
    ADP-TILIL7 BIOLOGICAL Phase PHASE1 Melanoma Stage III ClinicalTrials.gov
    Afamitresgene autoleucel GENETIC Phase PHASE1 Synovial Sarcoma ClinicalTrials.gov
    Autologous genetically modified AFPᶜ³³²T cells GENETIC Phase PHASE1 Hepatocellular Cancer ClinicalTrials.gov
    Letetresgene autoleucel (lete-cel, GSK3377794) DRUG Phase PHASE2 Neoplasms ClinicalTrials.gov
    afamitresgene autoleucel (previously ADP-A2M4) GENETIC Phase PHASE2 Synovial Sarcoma ClinicalTrials.gov
    Non-conforming afamitresgene autoleucel GENETIC Preclinical Synovial Sarcoma ClinicalTrials.gov
    Letetresgene autoleucel DRUG Phase PHASE2 Neoplasms ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Adaptimmune Therapeutics plc
    • CIK: 0001621227
    • Ticker Symbol: ADAP
    • Period End Date: 2022-05-25
    • Document Type: 8-K

Search

News categories